$110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter
Wall Street brokerages predict that Synlogic Inc (NASDAQ:SYBX) will post $110,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Synlogic’s earnings. The lowest sales estimate is $100,000.00 and the highest is $110,000.00. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Synlogic will report full-year sales of $110,000.00 for the current financial year, with estimates ranging from $2.20 million to $2.44 million. For the next fiscal year, analysts anticipate that the firm will post sales of $370,000.00 per share, with estimates ranging from $300,000.00 to $400,000.00. Zacks’ sales averages are an average based on a survey of analysts that follow Synlogic.
A number of brokerages have weighed in on SYBX. Zacks Investment Research upgraded Synlogic from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Wedbush began coverage on Synlogic in a report on Monday, November 27th. They issued an “outperform” rating and a $20.00 price objective on the stock. ValuEngine lowered Synlogic from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Piper Jaffray Companies began coverage on Synlogic in a report on Monday, January 29th. They issued an “overweight” rating and a $16.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Synlogic has an average rating of “Hold” and an average price target of $18.75.
Shares of Synlogic (SYBX) traded down $0.13 during mid-day trading on Friday, reaching $9.95. The company’s stock had a trading volume of 90,611 shares, compared to its average volume of 151,753. The stock has a market cap of $220.35, a price-to-earnings ratio of -1.07 and a beta of 2.18. Synlogic has a 12 month low of $8.76 and a 12 month high of $23.00.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/03/14/110000-00-in-sales-expected-for-synlogic-inc-sybx-this-quarter.html.
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.